Hansa Biopharma AB (publ) PEG Ratio

The latest PEG ratio for HNSBF is -10.26. That is below the Healthcare sector average of 27.75. Investors often review this figure alongside Hansa Biopharma AB (publ)'s historical trend and sector peers before judging valuation or financial health.

Against Healthcare companies, HNSBF currently prints -10.26 for PEG ratio, while the sector average sits near 27.75. That is roughly 137.0% below the sector mean. Large gaps often invite a closer look at Hansa Biopharma AB (publ)'s growth, margins, and balance sheet.

A PEG ratio of -10.26 for Hansa Biopharma AB (publ) is not 'good' or 'bad' on its own. Compare it with the peer average (27.75) and with HNSBF's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.

After noting HNSBF's PEG ratio (-10.26), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Hansa Biopharma AB (publ)'s PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.